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CD164 and FCRL3 Are Highly Expressed on
CD4þCD26 T Cells in Se´zary Syndrome Patients
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Brian Kim1, Tzvete Dentchev1, Satoshi Nagata4, Tomoko Ise4, Louise C. Showe2 and Alain H. Rook1
Se´zary syndrome (SS) cells express cell surface molecules also found on normal activated CD4 T cells. In an effort
to find a more specific surface marker for malignant SS cells, a microarray analysis of gene expression was
performed. Results showed significantly increased levels of mRNA for CD164, a sialomucin found on human
CD34þ hematopoietic stem cells, and FCRL3, a molecule present on a subset of human natural T regulatory cells.
Both markers were increased in CD4 T cells from SS patients compared with healthy donors (HD). Flow cytometry
studies confirmed the increased expression of CD164 and FCRL3 primarily on CD4þCD26 T cells of SS
patients. Importantly, a statistically significant correlation was found between an elevated percentage of
CD4þCD164þ T cells and an elevated percentage of CD4þCD26 T cells in all tested SS patients but not in
patients with mycosis fungoides and atopic dermatitis or HD. FCRL3 expression was significantly increased only
in patients with high tumor burden. CD4þCD164þ cells displayed cerebriform morphology and their loss
correlated with clinical improvement in treated patients. Our results suggest that CD164 can serve as a marker for
diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression
correlates with a high circulating tumor burden.
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INTRODUCTION
Se´zary syndrome (SS), the leukemic variant of cutaneous
T-cell lymphoma (CTCL), is a malignancy of skin-trafficking
CD4 T cells. The diagnosis is based predominantly on tissue
biopsy showing atypical, epidermotropic CD4 T cells in the
epidermis, and by microscopic examination of peripheral
blood buffy coats for presence of lymphocytes with atypical
cerebriform appearing nuclei, known as Se´zary cells. In
addition to examination of tissue biopsies and blood, flow
cytometry is now a widely accepted diagnostic tool. However,
as SS cells express molecules also present on normal activated
CD4 T cells, diagnosis based on the phenotype of circulating
malignant cells can be difficult (Kim et al., 2005).
The malignant SS cells have been phenotyped as central
memory cells expressing CD4þCD26CD45ROþ . The
ability of the malignant cells to localize to the skin is facilitated
by skin addressins CLA (cutaneous lymphocyte antigen) and
CCR4 (chemokine (C-C motif) receptor 4), whereas the pre-
sence of CCR7 facilitates entry into lymph nodes (Ferenczi
et al., 2002; Sokolowska-Wojdylo et al., 2005a, b; Campbell
et al., 2010). Advancing disease in SS patients correlates with
the gradual decline in the TCR repertoire, eventually resulting
in the presence of malignant CD4 T cells expressing a single
TCR Vb (Yawalkar et al., 2003). Furthermore, molecules such
as NKp46 and CD158k/KIR3DL2, receptors originally identified
on natural killer cells, ganglioside GD3 (CD60), and syndecan
4 (SD-4), present on activated normal T cells, were also found
to be expressed at elevated levels mainly in SS patients with
high tumor burden (Poszepczynska-Guigne et al., 2004;
Campbell et al., 2010; Scala et al., 2010; Bensussan et al.,
2011; Chung et al., 2011). Interestingly, T-plastin, an intracel-
lular protein, has been found exclusively in the malignant
circulating CD4 T cells in SS patients, but its intracellular
expression and lack of specific antibodies applicable for flow
cytometry diminish its usefulness as a diagnostic marker
(Kari et al., 2003; Su et al., 2003).
The identification of a clonal malignant TCR Vb population
of CD4 T cells in patients facilitates diagnosis and monitoring
of the Se´zary cells. However, SS patients without an identifi-
able circulating clone can pose a diagnostic and therapeutic
monitoring challenge, particularly as loss of CD26 is indica-
tive of the malignant cells, but it does not distinguish them
from normal populations of CD4þCD26 cells present in
the circulation (Bernengo et al., 2001; Jones et al., 2001;
Sokolowska-Wojdylo et al., 2005b).
In our attempt to find a specific surface marker for
malignant cells, CD4 T cells isolated from SS patients and
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healthy donors (HD) were subjected to microarray analysis of
global gene expression. These studies revealed that CD164
and FC-receptor-like 3 (FCRL3) were expressed at significantly
higher levels in CD4 T cells of patients as compared with HD.
CD164, a sialomucin adhesion receptor demonstrated on a
population of CD34þ hematopoietic progenitor cells, has
been reported to be expressed in o3% of peripheral CD3
T cells in healthy volunteers (Watt et al., 1998; Zannettino
et al., 1998). FCRL3 is a member of the FCRL gene family
encoding proteins FCRL 1–6 that are homologous to the
classical Fc receptors. FCRL3 expression is found in 40% of
naturally occurring human CD4þCD25þ Foxp3þ T regula-
tory cells, and functional studies showed that CD4þCD25þ
FCRL3þ cells are nonresponsive to anti-CD3/CD28, IL-2,
phytohemagglutinin, or concanavalin A stimulation (Nagata
et al., 2009). Subsequent studies published by Swainson et al.
(2010) demonstrated that FCRL3þ cells exhibit a CD4þ
memory T-cell phenotype and that expression of FCRL3 corre-
lates with high levels of programmed cell death-1 receptor.
In this study we provide evidence that CD164 may serve as
an early detection marker for SS in patients with low-to-high
tumor burden, and that FCRL3 expression correlates with
disease progression.
RESULTS
Increased mRNA expression of CD164 and FCRL3 genes in CD4
T cells from SS patients as assessed by microarray analysis and
QRT–PCR
We performed a microarray analysis of global gene expression
on CD4 T cells isolated from SS patients to identify surface
markers specific for the malignant cells. We compared gene
expression in CD4 T cells from patients with high tumor
burden (n¼2, X50% of malignant cells in circulation),
medium tumor burden (n¼2, 50–20% of malignant cells),
and low tumor burden (n¼ 2, p20% of malignant cells) and
in HD (n¼ 3).
A total of 1,219 genes were identified as significantly
differentially expressed (Po0.05, false discovery rate (FDR)
o10%) and differed by at least 80% of the levels between
patients with high, medium, and low tumor burden and HD.
We chose two genes coding for cell surface molecules not
previously associated with CTCL. CD164 exhibited a significant
difference between all 6 SS patient samples and 3 HD
(P¼0.004, FDR¼7%). FCRL3 was the most differentially
expressed gene between patients with high and medium tumor
burden versus normal samples (P¼0.006, FDR¼10%), but was
less informative for patients with low tumor burden (Figure 1).
To validate the expression of CD164 and FCRL3 on the SS
malignant cells, we assessed mRNA levels for these genes in
CD4 T cells of 11 patients with high tumor burden, 16 with
medium-to-low tumor burden (6 medium tumor burden and
10 low tumor burden), and 9 HD by quantitative real-time
reverse-transcriptase–PCR (QRT–PCR). In the same cohort of
patients, we also assessed expression of T-plastin. As shown in
Figure 2, CD164 was significantly expressed in the cells of
patients with high, medium, and, importantly, low tumor
burden compared with healthy controls. FCRL3, as well as
T-plastin, were both expressed by CD4 T cells from patients
with high-to-medium but not low tumor burdens. These data
strongly suggest that malignant cells, particularly in patients
with advanced disease, express all three molecules.
Of note, in addition to CD164, FCRL3, and T-plastin, we
also assessed mRNA expression of SD-4 and NKp46
(Bensussan et al., 2011; Chung et al., 2011). SD-4 mRNA
expression was significantly increased in patients compared
with HD (P¼0.01), whereas NKp46 mRNA was
inconsistently expressed and not significantly increased
among SS patients (data not shown).
The acquisition of CD164 correlates with the loss of CD26
expression in SS patients; FCRL3 is present mainly in CD4 T cells
in patients with high tumor burden
Peripheral blood mononuclear cells (PBMCs) from SS patients
(high/medium/low tumor burden), mycosis fungoides (MF)
patients without known blood involvement, HD, and atopic
dermatitis (AD) patients were analyzed for the presence of
CD164 and CD26 on their CD4 T cells by flow cytometry. The
percentages of CD4þCD164þ as well as CD4þCD26
T cells were significantly increased in SS patients when
compared with MF and AD patients or HD (P-values for both
markers were o0.0001). Importantly, we found a statistically
significant correlation between an elevated percentage of
CD4þCD164þ T cells and an elevated percentage of
CD4þCD26 T cells in all 59 SS patients (Pearson’s
correlations: rho¼ 0.674, Po0.0001) but not in MF patients
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Figure 1. Increased mRNA expression of CD164 and FCLR3 genes in CD4 T
cells from Se´zary syndrome patients as assessed by microarray analysis. The
expression of CD164 and FCRL3 in CD4 T cells isolated from peripheral blood
mononuclear cells (PBMCs) of Se´zary patients with high tumor (HT), medium
tumor (MT), and low tumor (LT) burden and healthy donors (HD). Normalized
signals with the indicated genes are shown.
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(n¼ 10, rho¼  0.372, P¼0.33) or HD (n¼ 14, rho¼
 0.39, P¼ 0.21). Figure 3a shows percentages of CD4þ
CD26 and CD4þCD164þ T cells detected in SS patients
(mean CD26 : 59.2%, SEM: 3.7, mean CD164þ : 34.7%,
SEM: 3.7), MF patients (mean CD26 : 36.6%, SEM: 4.6,
mean CD164þ : 3.0%, SEM: 0.7), and HD (mean CD26 :
19.6%, SEM: 2.6, mean CD164þ : 1.2%, SEM: 0.2). Com-
pared with MF and HD, the percentage of CD4þCD26
T cells in SS patients was also significantly increased (Po0.02).
Consistent with the data shown in Figure 3a, CD164 protein
was detected on the surface of patients with high (n¼ 37)
medium (n¼14), and, importantly, low (n¼8) tumor burden
and was significantly increased in all three groups compared
with HD or MF patients without peripheral blood involvement
and in AD patients (Figure 3b). Interestingly, CD164 expres-
sion was not detected in CD4 T cells from six AD patients
(mean CD164þ : 1.2%, SEM: 0.50). It should be mentioned
that only 4 out of 59 SS patients (6.8%) were low expressers of
CD164, with o5% of CD4 T cells expressing CD164 (mean:
1.8%, SEM: 0.84).
A statistically significant increase in FCRL3 protein expres-
sion was found only in patients with a high tumor burden in
the circulation (Figure 3c). On average, 46.6% of CD4 T cells
from patients with high tumor burden expressed FCRL3 (SEM:
6.35) on their surface compared with 5.1% of CD4þ
FCRL3þ cells in patients with medium tumor burden (SEM:
1.58) and 2.7% of CD4þ FCRL3þ cells in patients with low
tumor burden (SEM: 0.87). The mean expression of FCRL3 on
CD4 T cells from MF patients and HD was 13% (SEM: 3.5)
and 5.6% (SEM: 2.0), respectively (Figure 3c).
The detailed flow cytometric analysis confirmed the results
suggested by the data shown in Figure 3a–c that CD164 and
FCRL3 are mainly expressed on CD4þCD26 T cells
(Figure 3d and Supplementary Table S1 online).
Among patients with high tumor burden, whose CD4 T cells
were mainly CD26 negative and expressed a single TCRVb as
defined by antibodies, CD164 and FCRL3 were expressed
predominately on CD4þCD26Vbþ T cells (Figure 3d,
patient 1, upper panel). Similarly, in patients without an
identifiable TCRVb, including patients with low tumor burden,
CD164 was predominantly expressed on CD4þCD26
T cells (Figure 3d, patient 2, lower panel). FCRL3 expression
was rarely evident in CD4 T cells in patients with medium-
to-low tumor burden.
CD4þCD164þ cells display cerebriform morphology
CD4þCD164þ cells and CD4þCD164 cells were iso-
lated from PBMCs of highly leukemic patients and processed
to create 1-mm-thick section slides used for the assessment of
Se´zary cells. Representative photographs are shown in
Figure 4a and b. CD4þCD164þ , but not CD4þCD164
T cells, manifested a high degree of cerebriform morphology.
In addition, we sorted CD4 T cells into CD4þCD164þ and
CD4þCD164 cells, placed them on glass slides and
analyzed them for potential differences in cell size between
the two groups. As shown in Figure 4c and d, CD4þ
CD164þ T cells were much larger in size compared with
the CD4þ CD164 T cells. Although the nuclear morphol-
ogy cannot be fully assessed using this method, the differences
in size between CD4þCD164þ and CD4þCD164 T
cells further suggest that CD4 CD164þ T cells may represent
the malignant population, a finding consistent with Clark et al.
(2011), who showed that malignant CTCL cells have a high-
scatter profile.
Clinical improvement in disease status of SS patients correlates
with a decreasing percentage of CD4þCD26CD164þ
FCRL3þ circulating T cells
We next attempted to determine whether clinical improve-
ment in disease status can be monitored by assessing changes
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Figure 2. CD164, FCRL3, and T-plastin mRNA expression in CD4 T cells from
Se´zary syndrome patients as assessed by quantitative real-time reverse-
transcriptase–PCR (QRT–PCR). CD4 T cells were isolated from peripheral
blood mononuclear cells (PBMCs) of 11 patients with high tumor burden
(HT; X50% malignant cells), 6 with medium tumor burden (MT; 50–20%
malignant cells), and 10 with low tumor burden (LT; p20% malignant cells),
and 9 healthy donors (HD). Total RNA was extracted from CD4 T cells
followed by QRT–PCR to assess mRNA levels. Fold difference for CD164,
FCRL3, and T-plastin is calculated versus expression levels in cells from
healthy volunteers. Error bars represent SEM.
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Figure 3. The acquisition of CD164 correlates with the loss of CD26 on CD4 T cells of patients; FCRL3 is predominantly expressed in CD4 T cells of patients
with high tumor burden. The cell surface expression of CD26, CD164, and FCRL3 was assessed by flow cytometry. (a) Se´zary syndrome (SS) patients (n¼ 59)
demonstrate significantly higher percentages of CD4þCD164þ and CD4þCD26 T cells compared with mycosis fungoides (MF) patients (n¼ 10), or healthy
donors (HD; n¼14). (b) Percentage of CD4þCD164þ T cells is significantly higher in patients with high tumor (HT; n¼37), medium tumor (MT; n¼ 14), and
low tumor (LT; n¼ 8) burden compared with MF, HD, or atopic dermatitis (AD) patients (n¼6). (c) Percentage of CD4þ FCRL3þ T cells is significantly higher
only in CD4 T cells of HT patients (n¼26) but not in MT (n¼ 15) or LT (n¼7) patients as compared with HD. Results are expressed as mean with 95% confidence
interval. (d) CD164 and FCRL3 are predominately expressed on CD4þCD26 and CD4þCD26-Vbþ T cells. Shown results are from one representative patient
(out of 7) with a TCRVb defined by antibody (upper panel) and from one representative patient (out of 14) whose TCRVb was not defined by antibody (lower
panel). The peripheral blood mononuclear cells (PBMCs) of patients were collected before initiation of systemic therapy at the University of Pennsylvania.
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in the expression of CD164 and FCRL3 in the CD4 T cells of
patients. We focused on three originally highly leukemic
patients who had achieved a complete clinical remission with
resolution of all skin lesions and lymphadenopathy while
being treated with multimodality immune therapy. As shown
in Figure 5, on completion of treatment, two patients with an
identifiable Vb clone experienced a marked decrease in the
percentage of VbþCD4 T cells (patients 1 and 2), and all
three patients had decreases in the percentages of CD26 ,
CD164þ , and FCRL3þ CD4 T cells. These results suggest
that the expression of CD164 as well as FCRL3 in the CD4
T cells of SS patients can serve as a surrogate marker of disease
progression and circulating tumor burden, and that these
molecules may be used to monitor therapeutic efficacy in
CTCLs.
DISCUSSION
Our data demonstrate previously unreported high expression
of CD164 and FCRL3 on CD4 T cells from SS patients.
Importantly, our results show a statistically significant correla-
tion between CD164 acquisition and loss of CD26 expression;
high CD164 expression correlates with increased percentages
of CD26 T cells.
The potential for CD164 to serve as a marker for malignant
cells is underscored by: (1) the presence of CD164 on CD4
T cells of SS patients with a wide range of tumor burdens;
(2) the absence of CD164 on CD4 T cells from HD and
patients with AD; (3) morphological examination of purified
CD4þCD164þ T cells demonstrating the morphology of
malignant Se´zary cells; and (4) the disappearance of CD4þ
CD164þ T cells in three patients who experienced clinical
remission as a result of treatment.
Recently, CD164 expression was shown in human prostate
cancer cells and in cell lines derived from human breast
carcinoma. It has been also identified as a new marker for
acute lymphoblastic leukemia (Havens et al., 2006; Coustan-
Smith et al., 2011; Leccia et al., 2012). There is evidence
suggesting an important role for CD164 in prostate cancer cell
metastasis and in the development of colorectal cancer
(Matsui et al., 2000; Havens et al., 2006).
It is not yet clear what drives the expression of CD164 on SS
CD4 T cells. Based on our preliminary results, TCR stimulation
with anti-CD3/28 or polyclonal stimulation with phytohemag-
glutinin does not play a key role in upregulating CD164
expression in the CD4 T cells of patients. In response to either
stimulus, the percent of CD4þCD164þ T cells rose from
CD4+CD164– CD4+CD164+
Figure 4. CD4þCD164þ cells demonstrate the phenotype of malignant
Se´zary cells. For assessment of cellular morphology, (a, b) CD4þCD164þ
cells (5 106, 85% purity) and CD4þCD164 cells (2.9 106, purity 69%)
from a patient with high tumor burden were recovered using an anti-PE
column. Cells were processed to obtain a 1-mm-thick section, stained with
hematoxylin and eosin (H&E), and assessed for the presence of malignant cells.
Cellular morphology was examined using an Olympus BX51 microscope.
Images were captured with a Leica DFC 420 camera. Data shown are from one
representative patient out of five. For size assessment, (c, d) CD4 T cells from
a patient with high tumor burden were sorted into CD4þCD164þ and
CD4þCD164 (purity of both populations 98%), placed on glass slides, air
dried, stained with H&E, and analyzed using a Zeiss Axiophot microscope.
Images were captured using a Leica DFC 450 camera. Shown images are from
one representative patient out of six. Bars¼ 100mm.
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Figure 5. Clinical remission of disease correlates with the disappearance
of CD4þCD26 T cells expressing Vb, CD164, and FCRL3. Peripheral
blood mononuclear cells (PBMCs) from three patients with high tumor burden
were analyzed by multicolor flow cytometry to assess the expression of the
molecules on CD3þ /CD4þ T cells. Samples of patient’s PBMCs were
collected before the onset of systemic treatment and during clinical remission.
Patient 1 (P1) received extracorporeal photopheresis (ECP), IFN-a, and psoralen
plus UVA (PUVA), whereas patients 2 and 3 (P2 and P3) received ECP, IFN-a,
and total skin electron beam therapy.
M Wysocka et al.
CD164 Inversely Correlates with CD26 Expression
www.jidonline.org 233
0.1% (unstimulated group) to 5.5%, whereas CD25 expression
increased from 2% (unstimulated) to nearly 40% (data not
shown). It is also highly unlikely that systemic treatment such
as IFN or extracorporeal photopheresis increases CD164 or
FCRL3 expression, as we observed longitudinal decreases,
rather than increases, in the percentages of CD4þCD164þ /
FCRL3þ T cells among SS patients over their treatment course
with these agents.
Interestingly, CXCL12 (chemokine (C-X-C motif) ligand 12)
has been shown to stimulate the expression of both CD164
mRNA and protein in human prostate cancer cells, but it
remains to be established whether it has a similar role in
CTCLs. CXCL12 was abundantly expressed in the skin of SS
patients as demonstrated by Narducci et al. (2006). Moreover,
inhibition of enzymatic activity of CD26 enhanced the
CXCL12-induced migration of the CTCL cell line Hut78
(Narducci et al., 2006). Our preliminary data showed increa-
sed CXCL12 mRNA expression in the skin of three patients
with high tumor burden and three with medium tumor burden
whose CD4 T cells were used in these studies as compared
with HD (M. Wysocka, unpublished data). Thus, it is con-
ceivable that increased levels of CXCL12 in SS patients may
contribute to the elevated CD164 expression, although it may
not be an exclusive factor. The presence of another factor,
presently unknown, contributing to the tumor transformation,
loss of CD26, and acquisition of CD164 expression in the
CD4 T cells of patients cannot be ruled out, given that patients
with a low tumor burden in the circulation have percentages
of CD4þCD26 cells comparable to HD, yet still express
CD164 in their CD4 T cells.
Considering that absence of CD26 and presence of CD164
on the cell surface enhances CXCL12-mediated cell migration,
our findings strongly suggest that CD164 defines a population
of malignant CD4 T cells with the ability to invade skin and
possibly lymph nodes and bone marrow.
The phenotype of CD4þ FCRL3þ T cells in SS patients
differs from the described phenotype of naturally occurring
T regulatory cells in that the freshly isolated cells from SS
patients typically lack Foxp3 expression. We found no
correlation between FCRL3 and CD25 expression in patients
with high tumor burden, as CD4 T cells were highly positive
for FCRL3 (482%) but only marginally so for CD25 (o10%).
However, the presence of FCRL3 protein on CD4 T cells from
this group of patients and the presence of FCRL3 mRNA in
patients with medium tumor burden may indicate a gradual
loss of responsiveness of patients’ CD4 T cells to cytokines and
TCR stimulation, as has been previously suggested (Fargnoli
et al., 1997; Wysocka et al., 2004). We previously showed
that some SS patients have an increased expression of
programmed death-1 receptor on CD4 T cells, a molecule
that has been associated with decreased immune responsive-
ness (Shimauchi et al., 2007; Samimi et al., 2010). Recently,
Chung et al. (2011) demonstrated that association of SD-4
present on SS patients’ CD4 T cells, with dendritic cell-
associated hepran sulfate proteoglycan-integrin ligand
(DC-Hil) leads to attenuation of TCR-induced proliferation of
CD4 T cells. We have found significantly elevated levels of
mRNA for SD-4 in our cohort of SS patients (data not shown),
supporting the notion that SD-4 may also contribute to this
unresponsive phenotype.
Currently, we do not have a full understanding of the
biological significance of FCRL3 expression in the CD4 T cells
of SS patients. Similarly, the functional significance of CD164
expression on patients’ cells awaits a better understanding.
However, the statistically significant expression of CD164 on
CD4 T cells from patients but not from HD, and the significant
correlation between acquisition of CD164 and loss of CD26
expression, all indicate that CD164 may be a potentially
interesting marker for malignant SS cells. Furthermore, our
preliminary data showing a lack of CD164 expression on CD4
T cells from six patients with severe-to-moderate AD suggests
that CD164 may be restricted to SS, but certainly further
studies are needed to fully assess this marker specificity. Our
future studies will focus on understanding the biological
significance of CD164 and FCRL3, particularly with regard
to their association with malignant transformation in CTCLs
and their expression in other inflammatory skin diseases.
In summary, the presence of a positive marker such as
CD164 that distinguishes between normal, immunocompetent
CD4 T cells and malignant CD4 T cells in SS will facilitate
earlier diagnosis as well as therapeutic monitoring of disease
status. It will also further our understanding of the underlying
mechanisms responsible for the transition from activated
normal CD4 T cells to malignant CD4 T cells and may
eventually lead to a more targeted SS therapy.
MATERIALS AND METHODS
Patients
SS patients were diagnosed on the basis of clinical, histopathologic,
and immunohistologic criteria (Murphy, 1988). To assess the numbers
of circulating malignant T cells, PBMCs of patients were analyzed by
flow cytometry for the presence of CD4þ /CD26 /CD7 cells and by
examination of 1mm sections of formalin-fixed peripheral blood buffy
coats for lymphocytes with atypical ceribriform appearing nuclei
(Introcaso et al., 2005). Patients with erythroderma and circulating
malignant T cells were defined to have SS (Olsen et al., 2007).
Donation of peripheral blood samples by patients and healthy
volunteers was according to protocols approved by the University
of Pennsylvania Institutional Review Board.
The studies were conducted in accordance with the Declaration of
Helsinki Principles, and all participants provided written informed
consent.
Isolation of CD4 T cells and CD4þCD164þ cells
CD4 T cells from patients or healthy volunteers were isolated from
freshly collected PBMCs as previously described, using Dynal CD4
Positive Isolation Kit (Invitrogen Dynal, Oslo, Norway) (Rook et al.,
1995). Pure CD4 T cells were used in microarray and QRT–PCR
studies. To assess cellular morphology, CD4 T cells were stained with
anti-CD164-PE antibody and recovered using anti-PE microbead
columns from Miltenyi Biotec (Auburn, CA) or sorted using BD
(San Jose, CA) FACS Aria II SORP into CD4þCD164þ and CD4þ
CD164 cells. CD4 T cells were isolated from patients currently
undergoing treatment in the CTCL clinic. Patients were routinely
treated with extracorporeal photopheresis combined with Bexarotene,
IFN-a, or IFN-g.
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Preparation of cells for morphological assessment
For assessment of cellular morphology, CD4þCD164þ T cells or
CD4þCD164 T cells, previously separated using anti-PE columns,
were processed in JB4 to obtain 1-mm-thick sections according to the
standardized procedure for analysis of the presence of Se´zary cells in
peripheral blood buffy coats adapted by the Division of Dermato-
pathology, Department of Dermatology, University of Pennsylvania
(Philadelphia, PA) For size assessment, CD4þCD164þ T cells or
CD4þCD164 T cells, previously sorted, were placed on glass
slides, air-dried, hematoxylin and eosin stained, and microscopically
analyzed.
Flow cytometry analysis
To analyze the phenotype of CD4 T cells from patients and HD,
PBMCs were stained with antibodies anti-CD3, anti-CD4, anti-CD26,
anti-CD164, and anti-CD25 purchased from BD Biosciences
(San Jose, CA) and anti-FCRL3. Production and characterization of
anti-FCRL3 antibody, H5, has been described previously (Nagata
et al., 2009). To assess the viability of analyzed cells, the LIVE/DEAD
Fixable Aqua Dead Cell Stain Kit from Invitrogen (Grand Island, NY)
was used.
Cells were analyzed with the LSRII flow cytometer (Becton
Dickinson, San Jose, CA) at the Flow Cytometry and Cell Sorting
Core, Abramson Cancer Center, University of Pennsylvania. A total of
100,000 events were collected to analyze CD4 T cells. The data were
further analyzed by FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
Pearson’s correlation coefficients were estimated to assess the
correlation between CD164þ and CD26 expression on CD4 T
cells. Student’s t-test was used to assess differences between
groups in levels of expression. Tests were considered statistically
significant using a two-sided P-value of 0.05. The statistical package R
(www.r-project.org) was used for analysis.
Microarray studies: preparation of CD4 T-cell RNA
Gene expression was analyzed in CD4 T cells from six SS patients
and three HD. RNA was processed as previously described and
hybridized on Illumina (Valencia, CA) Human WG 8v2 microarray
chips (Showe et al., 2009). All arrays were processed in the Wistar
Institute Genomics Facility (Philadelphia, PA).
Data preprocessing
Array data were processed by Illumina’s BeadStudio software and
expression levels exported for analysis. The gene-wise, median
correlation of each array compared with all other arrays was
computed to ensure that no outliers existed within the data. The
expression levels were then quantile normalized and noninformative
probes (those with detection P-value 40.05 in all samples) were
removed to reduce experimental noise. Ultimately, 23,050 probes
that targeted known genes were used in our analysis.
Gene expression analysis
A one-way analysis of variance test was conducted on the data to
identify genes differentially expressed between any tumor samples
versus HD or high/medium tumor burden samples versus HD sepa-
rately. FDR was estimated using the procedure of Storey and Tibshirani
(2003). The data analysis was conducted using functions of MATLAB
7.2 (Natick, MA) and significance was defined at Pp0.05 and
FDR p10%.
Quantitative real-time RT–-PCR
Total RNA was extracted from CD4 cells using TRIzol Reagent
(Ambion, Grand Island, NY). Complementary DNA was synthesized
from 1mg of RNA using High Capacity RNA to cDNA Kit (Applied
Biosystems, Grand Island, NY). QRT–-PCR was performed using
Taqman gene expression assays: 18s rRNA, CD164, FCRL3, T-plastin,
SD-4, and NKp46 according to the manufacturer’s protocols (Applied
Biosystems). Comparison of expression levels of a gene between pairs
of groups was done using the DCt method.
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